Skip to main content
SynAct Pharma logo

SynAct Pharma — Investor Relations & Filings

Ticker · SYNACT ISIN · SE0008241491 LEI · 549300RRYIEFEQ72N546 ST Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2026-05-08 Regulatory Filings
Country SE Sweden
Listing ST SYNACT

About SynAct Pharma

https://synactpharma.com/en/

SynAct Pharma is a clinical-stage biotechnology company developing innovative medicines designed to resolve inflammation rather than solely inhibit it. The company's approach focuses on resolution therapy by leveraging melanocortin biology to restore immune balance. Its lead candidate, Resomelagon (AP1189), is a once-daily oral therapy that selectively activates melanocortin receptors on key immune cells. SynAct Pharma's development programs target a broad range of inflammatory conditions, including early intervention in chronic diseases to limit progression and the modulation of hyperinflammatory stages in acute viral diseases to reduce the risk of severe organ dysfunction.

Recent filings

Filing Released Lang Actions
Kallelse till årsstämma i SynAct Pharma AB
Regulatory Filings
2026-05-08 English
Notice of annual general meeting in SynAct Pharma AB
Regulatory Filings
2026-05-07 English
SynAct Pharmas valberedning inför årsstämman 2026
Board/Management Information Classification · 80% confidence The document is a press release announcing the composition changes of the nomination committee ahead of the company’s Annual General Meeting. This is an announcement concerning the company’s governance structure (the nomination committee), which falls under Board/Management Information: announcement of changes in board-related bodies or senior management. Therefore, it best fits MANG.
2026-04-23 Swedish
SynAct Pharma’s Nomination Committee ahead of the 2026 Annual General Meeting
Governance Information Classification · 70% confidence The document is a press release announcing the composition of the Nomination Committee for the upcoming Annual General Meeting. It concerns internal governance structure—specifically a committee of the board—rather than financial results, dividends, or a full report. It does not announce director or senior management appointments per se, but details governance arrangements under board structure. This aligns with the Governance Information category.
2026-04-23 English
Annual Report 2025
Annual Report Classification · 100% confidence The document is titled 'ÅRSREDOVISNING SYNACT PHARMA AB' which translates to 'Annual Report SynAct Pharma AB'. It contains detailed sections typical of an annual report such as CEO letter, business description, vision and mission, historical milestones, financial statements (income statement, balance sheet, cash flow), notes, alternative key figures, auditor's report, and corporate governance report. The document covers the fiscal year 2025-01-01 to 2025-12-31, indicating it is a full-year report. The length is substantial (15,000 characters), and it includes comprehensive financial and operational information, not just an announcement or summary. Therefore, this document fits the definition of an Annual Report (10-K). FY 2025
2026-04-15 Swedish
Major Shareholding Notification 2026
Major Shareholding Notification Classification · 95% confidence The document is a flagging notice (“flaggningsmeddelande”) published by Finansinspektionen under Swedish law (LHF 4 kap. 2§), detailing a change in significant share ownership by Thomas Ringberg in SynAct Pharma AB (stating before and after holdings, threshold crossed, legal references). This clearly fits the definition of a Major Shareholding Notification.
2026-04-07 Swedish

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.